Janux Therapeutics (NASDAQ:JANX) Shares Up 4.7%

Janux Therapeutics, Inc. (NASDAQ:JANX) shot up 4.7% during mid-day trading on Thursday . The stock traded as high as $11.04 and last traded at $11.04. 64,315 shares were traded during trading, a decline of 46% from the average session volume of 118,949 shares. The stock had previously closed at $10.54.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on JANX. HC Wainwright reiterated a “buy” rating and set a $35.00 price objective on shares of Janux Therapeutics in a research report on Wednesday, August 9th. Wedbush restated an “outperform” rating and issued a $24.00 target price on shares of Janux Therapeutics in a research report on Thursday, August 10th.

Janux Therapeutics Stock Up 0.1 %

The stock has a market capitalization of $507.56 million, a price-to-earnings ratio of -6.75 and a beta of 1.52. The business has a 50-day simple moving average of $12.11 and a two-hundred day simple moving average of $13.25.

Janux Therapeutics (NASDAQ:JANX) last released its earnings results on Tuesday, August 8th. The company reported ($0.42) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.10. The firm had revenue of $1.06 million during the quarter, compared to the consensus estimate of $1.25 million. Janux Therapeutics had a negative return on equity of 21.22% and a negative net margin of 862.89%. On average, analysts forecast that Janux Therapeutics, Inc. will post -1.81 EPS for the current year.

Insider Buying and Selling at Janux Therapeutics

In related news, Director Ra Capital Management, L.P. purchased 495,008 shares of the company’s stock in a transaction on Wednesday, July 19th. The shares were bought at an average price of $12.46 per share, with a total value of $6,167,799.68. Following the completion of the acquisition, the director now owns 8,117,246 shares of the company’s stock, valued at $101,140,885.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 35.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. American International Group Inc. increased its holdings in shares of Janux Therapeutics by 25.3% in the first quarter. American International Group Inc. now owns 8,813 shares of the company’s stock valued at $126,000 after buying an additional 1,782 shares in the last quarter. Barclays PLC lifted its holdings in shares of Janux Therapeutics by 93.2% in the first quarter. Barclays PLC now owns 8,904 shares of the company’s stock valued at $108,000 after purchasing an additional 4,296 shares in the last quarter. BNP Paribas Arbitrage SNC purchased a new stake in shares of Janux Therapeutics in the third quarter valued at $103,000. Wells Fargo & Company MN lifted its holdings in shares of Janux Therapeutics by 115.0% in the second quarter. Wells Fargo & Company MN now owns 6,633 shares of the company’s stock valued at $79,000 after purchasing an additional 3,548 shares in the last quarter. Finally, Citigroup Inc. lifted its holdings in shares of Janux Therapeutics by 935.2% in the second quarter. Citigroup Inc. now owns 5,787 shares of the company’s stock valued at $69,000 after purchasing an additional 5,228 shares in the last quarter. Institutional investors own 75.39% of the company’s stock.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on proprietary Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients suffering from cancer. Its lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2.